LBF20406OX02: Difference between revisions
No edit summary |
No edit summary |
||
Line 5: | Line 5: | ||
{{Metabolite | {{Metabolite | ||
|LipidBank=DFA8157 | |LipidBank=DFA8157 | ||
|LipidMaps= | |LipidMaps=LMFA03060019 | ||
|SysName=12-oxo-5Z,8Z,10E,14Z-eicosatetraenoic acid | |SysName=12-oxo-5Z,8Z,10E,14Z-eicosatetraenoic acid | ||
|Common Name=&&12-oxo-5Z,8Z,10E,14Z-eicosatetraenoic acid&& | |Common Name=&&12-oxo-5Z,8Z,10E,14Z-eicosatetraenoic acid&& |
Revision as of 04:24, 16 February 2010
LipidBank Top (トップ) |
Fatty acid (脂肪酸) |
Glycerolipid (グリセロ脂質) |
Sphingolipid (スフィンゴ脂質) |
Journals (雑誌一覧) |
How to edit (ページの書き方) |
IDs and Links | |
---|---|
LipidBank | DFA8157 |
LipidMaps | LMFA03060019 |
CAS | |
KEGG | {{{KEGG}}} |
KNApSAcK | {{{KNApSAcK}}} |
mol | LBF20406OX02 |
12-oxo-5Z,8Z,10E,14Z-eicosatetraenoic acid | |
---|---|
Structural Information | |
12-oxo-5Z,8Z,10E,14Z-eicosatetraenoic acid | |
| |
12-OxoETE/12-KETE | |
Formula | C20H30O3 |
Exact Mass | 318.21949482599996 |
Average Mass | 318.4504 |
SMILES | C(CC=CCC(C=CC=CCC=CCCCC(O)=O)=O)CCC |
Physicochemical Information | |
12-OxoETE is synthesized by human platelets and Aplaysia nervous tissue after incubation with arachidonic acid Falgueyret_JP et al. Fruteau_de_Laclos_B et al.. Microsomal fractions of various tissues will reduce 12-oxoETE to 12(S)-HETE or a mixture of 12(S)- and 12(R)-HETE Falgueyret_JP et al. Falgueyret_JP et al.. | |
12-OxoETE induces a rapid, dose related increase of cytoplasmic free calcium via a leukotriene B4 receptor or a common activation sequence Naccache_PH et al.. | |
Spectral Information | |
Mass Spectra | |
UV Spectra | lmax: 280nm e: 30,000 |
IR Spectra | |
NMR Spectra | |
Other Spectra | |
Chromatograms |
Reported Metabolites, References | |||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|